From ₹ 19 to ₹ 299, this stock soars 1475% in 5 years; Ventura Sees Another 53% UPSide

Multibagger Stock Wanbury has emerged as one of the most astonishing success stories on Dalal street, transforming itself from an obscure penny stock into a headline-maker in five years. From trading at just 19 in June 2020, The stock has surgged more than 1,475 percent to hover Around 299.35 in Recent Sessions. This translates to a remarkable 1 Lakh Investment Growing to over 15.75 lakh.

A stock in Momentum: One-Year Gains, Monthly SURGE

Over the past year alone, wanbury has rallied near 93 percent, deliverying impressive returns to investors in a staggered but consistent manner. The Multibagger Stock Has Climbed 4 Percent in June So far, Folling a 25.5 Percent Gain in May, A 1 Percent Rise in April, and An Eye-Catching 37 Percent Surge in March. Despite Facing Setbacks Earlier this year – Dropping 25 percent in January and 21 Percent in February – WANBURY HAS Bounced Back Strongly, Showcasing Persistent Buying Interest.

The stock hit its 52-wheek high of 330 last month and its 52-wheek low of 151.10 in July 2024. From its covid-ra 18 per share, the stock has multipled near 1,565 percent – Cementing its multibagger credentials.

Ventura predicts 53% upside

Domestic Brokerage Ventura Securities Has Initiated Coverage on Wanbury Ltd with a Bulish ‘Buy’ Rating, Setting a price target of 458 over the next 24 months. With the stock currently Around 299.35, this target implies a potential UPSIDE of 53 Percent. Ventura Sees Robust Earnings Potential, Backed by Strong Growth in Bot Its API and Branded Formutions segments.

According to the brokege, wanbury’s revenue is projection to grow at a cagr of 20 percetic from fy25 to fy28, Reaching 1,046 Crore. Ebitda and Net Profit are expected to post even sharper growth at 33 percent and 51 percent Cagr, respectively. By FY28, The company’s ebitda is expected to touch 177 Crore, with Net Profit at 104 Crore. Margins, Too, Are Set to Expand – Ebitda Margin is Seen Improving by 310 Basis Points to 15.5 Percent, While Net Margin May Increase by 290 Basis points to 10 percent.

As per the brokerage, wanbury’s strength lies in its Leadership in Active Pharmaceutical ingredients (APIS), with a Global Market Share of 10 Percent in Metformin and 30 percent. The API Division, which larGely catters to expert markets, is expected to grow at a 16 percent cagr, reaching 819 Crore by FY28.

Its domestic branded formulations business is growing at an even faster clip. Focused on high-margin chronic therapies, this segment is projection to expand at a 47 percent cagr to 227 Crore by FY28, Driven by New Product Launches and Broader Customer Outreach, It Further Stated.

The company is also recovering from Past Setbacks, Particularly its Troubled Spanish Formulations Venture. A return to profitability in fy24 and positive net worth a successful turning. Ventura Attributes Wanbury’s Revival to Operational Efficiency and Strategic Debt Refinancing.

Looking ahead, ventura pointed out that the company has allocated 165 Crore for a brownfield expansion at its tanuku plant, expected to be implemented between fy26 and fy28. This aligns with its strategy of maintaining an asset-light model while scaling up production capabilites.

Disclaimer: The views and recommendations made about individual analysts or broking companies, and not of Mint. We Advise Investors to Check With Certified Experts Before Making Any Investments Decisions.